Neurovalens, a global healthtech company headquartered in Belfast and San Diego, has raised £5.1 million in funding, led by IQ Capital. Wharton Asset Management Company, The Angel CoFund (ACF), Techstart Ventures, Clarendon Fund Managers, and the Government’s Future Fund also contributed to the funding round, which will be used to expand on the success of Neurovalens’ initial clinical trials and develop the technology’s application for other conditions.